Medtronic Diabetes - Healthcare Leadership Council ·
Transcript of Medtronic Diabetes - Healthcare Leadership Council ·
Medtronic Diabetes: Who We Are What We Do and Where are We GoingWho We Are, What We Do and Where are We Going
Robert A. Vigersky, M.D.Medical Director, Medtronic Diabetes
P t P id t E d i S i tPast-President, Endocrine SocietyColonel (ret) U.S. Army Medical Corps
May 18, 2015
Medtronic: Global Medical Technology LeaderMedtronic: Global Medical Technology LeaderNumber of employees:
85,000+85,000Number of countries operating in:
160+160500,000+patientsNumber of patents:Number of patents:
53,000+Research and development spend:
$$2BCharitable contributions:
$80M$80MInformation reflects Medtronic fiscal year 2014 data and Covidien fiscal year 2014
data
Diabetes Care SolutionsDiabetes Care Solutions
Serving Insulin Pumps Continuous Glucose M it i
g500,000+patients
Monitoring
patients worldwide
ConnectedCare
Data Management
Slide 3 | Confidential
Care Management
Diabetes Care SolutionsDiabetes Care Solutions
“Artificial Pancreas”Closed LoopClosed Loop
I li P C i Gl M iInsulin Pump Continuous Glucose Monitor
Slide 4 | Confidential
Winning the Race to Closed LoopIntensive Insulin
Management
Winning the Race to Closed LoopHybrid Closed Loop
MiniMed 640GSmartGuard
MiniMed 530GThreshold Suspend
Stops insulin delivery when glucose levels fall
Stops insulin delivery when glucose levels are predicted to fall
Starts & stops insulin based on actual & e g ucose e e s a
below set thresholdare predicted to fall below set threshold
predicted values
Clinical Path: Continue pursuit of artificial pancreas
Consumer Path: Innovate around comfort, ease and cost across all segments
Personal and Professional Continuous Glucose Monitoring
Professional CGM Personal CGM
Guardian® CGM System
iPro®2
Personal and Professional Continuous Glucose Monitoring
Professional CGM Personal CGM
Guardian® CGM System
iPro®2
Looking Beyond A1C and BG Meter Readings
BG Meter Readings
CGM Reveals Insights Beyond BGs and A1C
l dMeter Avg: 100 SD: 40
SG A 154 SD 102
400
Continuous Glucose Sensor Readings
A1C: 7 5
SG Avg: 154 SD: 102
mg/
dL)
300
A1C: 7.5
Glu
cose
(
200
G
100
40
Target Glucose Range
9PM 6PM3PM12PM9AM6AM3AM
Time of Day
Midnight Midnight40
(2001) Kaufman Study
N b f Gl
( ) y
Study Design Study Duration: 6 months
Professional CGM Captures Excursions Missed by BG MetersOutcome
191
Number of Glucose Excursions Identified
Study Duration: 6 months
N: 47 pediatrics with type 1 Diabetes (A1C > 8.6%±1 1.6),
P f i l CGM( ),
intensive insulin therapy
3-day Professional CGM
Professional CGMBG Meter
7242
10
yevaluation and BG Meter Readings
Overall Night-time Compared highs and lows
identified with CGM versus BG
Professional CGM revealed up to 7x more night-time excursionsthan BG meters
Kaufman F, et. al. Diabetes Care. 2001;24(12):2030-4.
Clinicians used CGM data to adjust and optimize therapy
Professional CGM Helped Guide Bolus/Basal Therapy Modifications
Clinician Directed Change
Hypo treatment
Bolus or Rapid-acting Insulin
Basal or Long-acting Insulin
for Dawn Phenomenon
Correction Algorithm
Hypo treatment
for High Glycemic Foods
for High Fat Meals
for Dawn Phenomenon
Kaufman F, et. al. Diabetes Care. 2001;24(12):2030-4.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%
Personal and Professional Continuous Glucose Monitoring
Professional CGM Personal CGM
Guardian® CGM System
iPro®2
Personal Continuous Glucose Monitoring in Type 1 DM
Bailey TS et al. Diab Tech Ther 9:203-210, 2007
Personal Continuous Glucose Monitoring in Type 2 DM
Vigersky R. et al. Diab Care 35: 32-38, 2012
Driving Technology Breakthroughs Tomorrow
REDESIGN
Driving Technology BreakthroughsHybrid closed-loop system
Artificial pancreasToday
ump
and
CG
M
2014
Artificial pancreas
CGM for Type 2 in Primary Care
stin
tegr
ated
pu 2015
2013Yesterday
MiniMed 620G CG
M
1sMiniMed 640GSmartGuard technology
522/722MiniMed 530G
MiniMed 620G
stin
sulin
pum
p
pro
CG
M
1stre
al-ti
me
1st system to automatically
New pump platform in Japan
2003
2006502
1s 1st suspend insulin in U.S.
19831999
2003
This slide contains future products/technologies that are not available for commercial distribution...
The Medicare CGM Access Act of 2015, HR 1427
Creates Medicare Access for CGM • Stand-alone, SAP, APDSStand alone, SAP, APDS• Covers medically appropriate
populations
Establish Appropriate payment mechanism for CGM
P th f f t t h l• Pathway for future technology (APDS)
S t d H BillSenate and House Bills• H.R. 1427 Reps. Tom Reed, Diana
DeGette, and Ed Whitfield
• S. 804 Senators Susan Collins and Jeanne Shaheen
Thanks for Your AttentionThanks for Your Attention
| MDT Confidential16